Niclas Högberg and William ‘Obi’ Greenman on Evolving Strategies in Massive Bleeding Management
Niclas Högberg, Sales Director at Cerus, reposted from William “Obi” Greenman on LinkedIn:
”MASSIVE BLEEDING – ARE WE DRIFTING APART IN STRATEGY?
In the U.S., 5-day Pathogen-Reduced Cryoprecipitated Fibrinogen Complex (PRCFC) is beginning to reshape massive transfusion practice.
As the study included concluded:
- “PRCFC is ready to dispense and provides an immediate source of fibrinogen in critically bleeding patients with significant reductions in TAT. There is an added benefit of reduced wastage.”
This evolution enables clinicians to act within minutes — moving beyond ratio-driven MTPs toward targeted, function-based hemostatic resuscitation.
Across Europe and the Nordics, focus has instead shifted toward Whole Blood (WB) for trauma and pre-hospital use.
While physiologically balanced, WB reintroduces challenges with traceability, shelf life, and pathogen safety — factors that SoHO and IVDR will soon regulate more tightly.
As Europe strengthens its blood preparedness and resilience, the key question is:
- Are we innovating forward — or reinventing the past for convenience?”
William “Obi” Greenman, Chairman and Chief Executive Officer at Cerus, shared on LinkedIn:
”The expansion of INTERCEPT Fibrinogen Complex use in large U.S. hospitals is really encouraging given the meaningful impact on immediate fibrinogen delivery in critically bleeding patients.
With >50% improvements in delivery time and reduced wastage, the efficiencies gained are real and the hospital transfusion service teams love the product and can focus their valuable time on other critical activities.”
Read the full article here.
Article: Pathogen-reduced cryoprecipitate: Early experiences and inventory management
Authors: C. B. Webb, A. Javanbakht, D. Hanna, S. G. Yates, R. Zhang, S. Afraz, R. Sarode

Stay updated on all scientific advances with Hemostasis Today.
-
Feb 18, 2026, 16:47Sophia Delicou: Importance of Assessing Hemoglobin Functional Capacity Rather Than Total Levels
-
Feb 18, 2026, 16:32Cheng-Hock Toh: 5 Steps to Transform Transfusion Practice
-
Feb 18, 2026, 16:26Tareq Abadl: CMV and Transfusion – Leukoreduction vs CMV-Seronegative
-
Feb 18, 2026, 16:24Soroush Sohrabi: The Hidden Biology of Sclerotherapy and Mechanisms Beyond Endothelial Injury
-
Feb 18, 2026, 16:23Hamad Abbasi: Why are Coronary Stents so Expensive?
-
Feb 18, 2026, 16:08Carlos Doti: AstraZeneca’s Expanding Impact in Blood Cancer Care
-
Feb 18, 2026, 16:05Shiny K. Kajal: Routine vs Massive Transfusion Protocol
-
Feb 18, 2026, 16:03Maria Farid: Successful Consultative Hematology and Transfusion Medicine Workshop at PKLI
-
Feb 18, 2026, 15:59Ella Lawson: Could Erythritol Harm the Brain’s Blood Vessels?